Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Other groups are more public about their progress. Acceleron, a company based in Cambridge, MA, that is developing a myostatin inhibitor, says that it has already developed a test for research purposes that is capable of detecting the drug in blood. And scientists at the Center for Preventive Doping Research, German Sport University Cologne, are working on a test for SARMs.

Fortunately, scientists say that detecting abuse of these two new classes of drugs is likely to be easier than detecting two doping agents that have plagued the sports world in recent years. Erythropoietin, which stimulates growth of red blood cells and is used to treat anemia patients, is processed quickly by the body, making it difficult to detect.Human growth hormone, which boosts cell growth, is a naturally occurring hormone. Tests must be able to discriminate between the natural hormone and the pharmaceutically derived version. “People who are trying to cheat like to use a steroid naturally present in the body, because it makes it much more difficult for labs to detect,” says Don Catlin, founder of Anti-Doping Research, a nonprofit research institute based in Los Angeles.

Myostatin inhibitors present a particularly interesting case for WADA. In 2004, scientists published a paper describing an abnormally muscular German toddler who carried mutations in both copies of his myostatin gene. The boy’s mother, who had been a professional athlete, was found to have one defective copy of the gene, raising questions about how to deal with athletes who have naturally occurring genetic mutations that give them benefits similar to those offered by performance-enhancing drugs. “We have ethicists thinking about those issues and guiding us in the future,” says Rabin. “We need to maintain fair play for all competitors.” The issue is likely to grow as advances in genomics allow scientists to uncover additional variants linked to muscle, or other factors related to athletic ability.

17 comments. Share your thoughts »

Credit: AP Images/Doug Mills

Tagged: Biomedicine, cancer, drugs, medicine, sports, muscular dystrophy

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me